Efficacy, Safety, and Tolerability of Eslicarbazepine Acetate in the Recurrence Prevention of Bipolar I Disorder
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This was an extension study consisting of 2 parts. In Part I, all participants received
open-label treatment with BIA 2-093 900 mg once daily for 2 weeks. Part II followed a
double-blind, parallel-group design in which participants were randomly assigned to treatment
with BIA 2-093 300 mg, 900 mg, or 1800 mg once daily. Patients stable in remission continued
double-blind therapy until approximately 6 months after the last patient entered Part II.